AngioSoma to Organize Business to Enhance Future Success


Houston, TX, Sep 17, 2018 – AngioSoma (OTC: SOAN) today announced today will organize the business into three new business units to meet specific and emerging market opportunities: Pharmaceuticals, Nutraceuticals, and Cosmeceuticals.  These align with recently announced operational improvements and are set to be effective at the beginning of the company’s 2019 fiscal year.

“We have made great strides in the past six months to leverage our growing market strength and operational efficiencies,” said AngioSoma president and chief executive officer, Alex Blankenship. “This new structure will focus our resources to strengthen our in-market products and our developing pipeline to the market in the coming months with sustained revenue growth.”

The first new division, Pharmaceuticals, focused exclusively on delivering innovative pharma-based solutions for the rapidly-growing, multi-billion-dollar medical market, will provide industry-leading research and development to provide treatment for many serious medical problems.  Clinical trials continue to approve marketing Liprostin™, AngioSoma, Inc.’s patented flagship Pharmaceutical product that treats the arterial distress caused by diabetes, such as diabetic ulcers and amputations.

The second new division is Nutraceuticals, the nutritional arm of the company with a research and development department, along with departments for marketing, sales, service and support. Through its retail brand, SomaCeuticals™, the company already has two products on the market ( and will be expanding to five within the next six weeks.  The focus of this division is to provide nutritional support to men and women so their bodies can repair and replenish themselves in a safe and natural way.

The third new division of AngioSoma is Cosmeceuticals, which already has three products sold under its retail brand SomaCeuticals™.   This division will have the same departments as the Nutraceutical division: research and development, marketing, sales, service and support.  The main focus will be to provide innovative products that maintain the skins’ youthful, resilient appearance, giving women and men the ability to not only act young, but look young as well.


AngioSoma, Inc. (https://, a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our Somaceuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.


AngioSoma, Inc.

Alex Blankenship